Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus ophthalmic - Santen Pharmaceutical

Drug Profile

Sirolimus ophthalmic - Santen Pharmaceutical

Alternative Names: DE-109; MS-R001; Opsiria; Perceiva

Latest Information Update: 11 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacuSight
  • Developer Johns Hopkins University; MacuSight; Midwest Eye Institute; Santen Pharmaceutical
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Uveitis
  • Phase III Wet age-related macular degeneration
  • Discontinued Diabetic macular oedema; Dry eyes

Most Recent Events

  • 19 Nov 2018 Santen initiates the phase III LUMINA trial for Uveitis in USA (Intravitreous) (NCT03711929)
  • 19 Oct 2018 Santen plans the phase III LUMINA trial for Uveitis in the US in November 2018 (Intravitreous) (NCT03711929)
  • 21 Dec 2017 Santen Pharmaceutical receives complete response letter from the FDA for intravitreal sirolimus in Uveitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top